Disposition of 49569 shares by Gv 2017 Gp, L.l.c. of Verve Therapeutics subject to Rule 16b-3
| VERV Stock | USD 5.78 0.47 8.85% |
Slightly above 57% of all Verve Therapeutics' sophisticated investors are looking to take a long position. The analysis of the overall investor sentiment regarding Verve Therapeutics suggests that some traders are interested. Verve Therapeutics' investing sentiment can be driven by a variety of factors including economic data, Verve Therapeutics' earnings reports, geopolitical events, and overall market trends.
Verve |
Filed transaction by Verve Therapeutics Director. Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3
Read at macroaxis.com
Cash Flow Correlation
Verve Therapeutics' cash-flow correlation analysis can be used to evaluate the unsystematic risk during the given period. It also helps investors identify the Verve Therapeutics' relationships between the major components of the statement of changes in financial position and other commonly used cash-related accounts. When such correlations are discovered, they may help managers and analysts to enhance performance or determine appealing investment opportunities.Click cells to compare fundamentals
Verve Therapeutics Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Verve Therapeutics can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Verve Therapeutics Fundamental Analysis
We analyze Verve Therapeutics' financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Verve Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Verve Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Verve Therapeutics is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Verve Therapeutics Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Verve Therapeutics stock to make a market-neutral strategy. Peer analysis of Verve Therapeutics could also be used in its relative valuation, which is a method of valuing Verve Therapeutics by comparing valuation metrics with similar companies.
Peers
Verve Therapeutics Related Equities
| IPSC | Century Therapeutics | 20.74 | ||||
| CRBU | Caribou Biosciences | 8.91 | ||||
| BEAM | Beam Therapeutics | 5.26 | ||||
| SANA | Sana Biotechnology | 4.08 | ||||
| NTLA | Intellia Therapeutics | 3.26 | ||||
| CRSP | Crispr Therapeutics | 3.10 | ||||
| ADPT | Adaptive Biotechnologies | 0.88 | ||||
| RLAY | Relay Therapeutics | 0.84 | ||||
| BPMC | Blueprint Medicines | 0.50 | ||||
| EDIT | Editas Medicine | 0.45 | ||||
| PRME | Prime Medicine, | 1.20 |
Additional Tools for Verve Stock Analysis
When running Verve Therapeutics' price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.